EE200300136A - Kompositsioonid ja meetodid lipoproteiin (a) taseme alandamiseks plasmas ja kardiovaskulaarsete haiguste riskifaktorite vähendamiseks - Google Patents

Kompositsioonid ja meetodid lipoproteiin (a) taseme alandamiseks plasmas ja kardiovaskulaarsete haiguste riskifaktorite vähendamiseks

Info

Publication number
EE200300136A
EE200300136A EEP200300136A EEP200300136A EE200300136A EE 200300136 A EE200300136 A EE 200300136A EE P200300136 A EEP200300136 A EE P200300136A EE P200300136 A EEP200300136 A EE P200300136A EE 200300136 A EE200300136 A EE 200300136A
Authority
EE
Estonia
Prior art keywords
compositions
levels
methods
cardiovascular disease
risk factors
Prior art date
Application number
EEP200300136A
Other languages
English (en)
Inventor
Rath Matthias
Original Assignee
Rath Matthias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rath Matthias filed Critical Rath Matthias
Publication of EE200300136A publication Critical patent/EE200300136A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EEP200300136A 2000-10-03 2001-10-03 Kompositsioonid ja meetodid lipoproteiin (a) taseme alandamiseks plasmas ja kardiovaskulaarsete haiguste riskifaktorite vähendamiseks EE200300136A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23718600P 2000-10-03 2000-10-03
PCT/US2001/031203 WO2002028379A2 (en) 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases

Publications (1)

Publication Number Publication Date
EE200300136A true EE200300136A (et) 2003-08-15

Family

ID=22892673

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300136A EE200300136A (et) 2000-10-03 2001-10-03 Kompositsioonid ja meetodid lipoproteiin (a) taseme alandamiseks plasmas ja kardiovaskulaarsete haiguste riskifaktorite vähendamiseks

Country Status (24)

Country Link
US (2) US6693129B2 (et)
EP (1) EP1324753A2 (et)
JP (1) JP2004525080A (et)
KR (1) KR20030070003A (et)
CN (1) CN100421659C (et)
AU (2) AU1145202A (et)
BR (1) BR0114526A (et)
CA (1) CA2424880A1 (et)
CZ (1) CZ20031167A3 (et)
EE (1) EE200300136A (et)
HR (1) HRP20030348A2 (et)
HU (1) HUP0303040A3 (et)
IL (2) IL155238A0 (et)
MX (1) MXPA03002964A (et)
NO (1) NO20031510L (et)
NZ (2) NZ545806A (et)
PL (1) PL212479B1 (et)
RO (1) RO120567B1 (et)
RU (1) RU2289406C2 (et)
SK (1) SK5252003A3 (et)
TR (1) TR200300594T2 (et)
UA (1) UA77660C2 (et)
WO (1) WO2002028379A2 (et)
ZA (1) ZA200302772B (et)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047682A1 (fr) * 2000-12-14 2002-06-20 Sankyo Company, Limited Composition ameliorant les lipides sanguins
DE60214849T2 (de) * 2001-02-27 2007-04-26 Nutrition 21, Inc. Chromium/biotin behandlung von dyslipidämie
WO2003020260A1 (en) * 2001-08-31 2003-03-13 Metaproteomics, Llc Arginine compositions for coordinate modification of multiple cardiovascular risk factors
EP1534302A4 (en) * 2002-08-22 2009-01-07 Nutrition 21 Inc ARGININILICATE / INOSITOL COMPLEX AND ITS USE
US20080020035A1 (en) * 2002-08-28 2008-01-24 Kedar Prasad Micronutrient formulations and related methods of manufacture
US7635469B2 (en) * 2002-08-28 2009-12-22 Premier Micronutrient Corporation Micronutrient formulations for hearing health
EP1562555A2 (en) * 2002-10-24 2005-08-17 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
US20050053673A1 (en) * 2003-09-05 2005-03-10 Shrirang Netke Composition and method for facilitating bone healing
EP1675619A4 (en) * 2003-09-29 2010-10-06 Palmetto Pharmaceuticals Llc EXTENDED RELEASE ARGININE FORMULATIONS, METHODS OF MAKING, AND USES
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
JP2005225871A (ja) * 2004-01-16 2005-08-25 Sankyo Co Ltd 血中トリグリセライド又はホモシステインを低下させる医薬組成物
CA2572815A1 (en) * 2004-07-09 2006-01-19 Medicure International Inc. Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
JP4896531B2 (ja) * 2005-01-25 2012-03-14 第一三共ヘルスケア株式会社 血中ＣｏＱ１０量を増加させる医薬組成物
US7628984B2 (en) * 2005-02-17 2009-12-08 Premier Micronutrient Corporation Micronutrient formulations for pulmonary and heart health
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
KR100592719B1 (ko) * 2005-10-05 2006-06-28 케이에스엠기술 주식회사 하천의 생태계 보호용 이물질 유입방지 시설
US20070292493A1 (en) * 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
US20080207748A1 (en) * 2007-02-22 2008-08-28 Innovation Labs, Inc. Vitamin c preparation
PL2134351T3 (pl) 2007-03-13 2017-10-31 Jds Therapeutics Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2008139314A1 (en) * 2007-05-11 2008-11-20 Horphag Research (Luxembourg) Holding Sa Compositions and methods for treating joint disorders
US7867524B2 (en) * 2007-10-05 2011-01-11 David Rowland Energizing formulation
RU2377007C1 (ru) * 2008-06-23 2009-12-27 Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М" Средство для лечения и профилактики онкологических заболеваний и способ применения этого средства (варианты)
US20110091618A1 (en) * 2009-10-16 2011-04-21 Frito-Lay North America, Inc. Method for preventing oxidation and off flavors in high carotenoid foods
RU2468791C2 (ru) * 2011-02-24 2012-12-10 Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" Композиция, обладающая адаптогенным, общеукрепляющим и повышающим работоспособность действием
EA025844B1 (ru) * 2012-05-08 2017-02-28 Общество С Ограниченной Ответственностью "Лигур-М" Средство для коррекции гиперхолестеринемии
WO2015199537A1 (en) * 2014-06-24 2015-12-30 Dedraf Holding B.V. New mineral composition
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
WO2017139337A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
CN106213522A (zh) * 2016-08-05 2016-12-14 郑家福 营养保健品
US11344575B2 (en) * 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
MX2019002468A (es) 2016-09-01 2019-09-18 Jds Therapeutics Llc Composiciones de biotinato de magnesio y metodos de uso.
SE540582C2 (en) * 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
EP3398601A1 (en) * 2017-05-02 2018-11-07 Salmon Pharma GmbH Nicotinamide for treating dyslipidemia
CN108033939B (zh) * 2017-12-26 2020-09-11 上海共晶医药科技有限公司 生育酚与脯氨酸的共结晶及其制备方法
CN109092262B (zh) * 2018-08-28 2019-07-05 广州达济医学科技有限公司 低密度脂蛋白吸附微球及制备方法和吸附材料
AU2019371825B2 (en) 2018-11-02 2023-07-27 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
US20210196598A1 (en) * 2018-12-26 2021-07-01 Colgate-Palmolive Company Specific Co-Aggregation Inhibition by Arginine
EP4076413A1 (en) 2019-12-16 2022-10-26 Nutrition 21, LLC Methods of production of arginine-silicate complexes
WO2024003385A1 (en) 2022-07-01 2024-01-04 N.V. Nutricia Nutritional composition for neurodegeneration and neurotrauma

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356370A (en) * 1972-03-06 1974-06-12 Howard A N Methods and formulations for the treatment of obesity
US4414238A (en) * 1981-12-24 1983-11-08 Cutter Laboratories, Inc. Liquid elemental diet
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4891220A (en) 1988-07-14 1990-01-02 Immudyne, Inc. Method and composition for treating hyperlipidemia
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5230996A (en) * 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
EP1068868A3 (en) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
EP0891771A1 (en) * 1997-07-08 1999-01-20 Health Now, Inc. Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6299896B1 (en) * 2000-04-13 2001-10-09 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6361800B1 (en) * 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
ATE323479T1 (de) * 2000-06-16 2006-05-15 Matthias Dr Med Rath Zusammensetzung für die verhinderung der glattmuskelkrankheiten, die ascorbat, arginin und magnesium enthält
ES2261136T3 (es) * 2000-10-09 2006-11-16 Matthias Dr. Med. Rath Composicion terapeutica de ascorbato con lisina y arginina para prevencion y tratamiento del cancer.
CH694549A5 (de) * 2001-01-16 2005-03-31 Dr Matthias Rath Verwendung einer synergistischen Zusammensetzung, die Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeration.
EE200200585A (et) * 2001-02-14 2004-04-15 Rath Matthias Biokeemiliste ühendite kompositsioon ja selle raviotstarbeline kasutamine rakulise energiavahetuse parendamiseks
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells

Also Published As

Publication number Publication date
HRP20030348A2 (en) 2005-06-30
HUP0303040A2 (hu) 2003-12-29
NZ545806A (en) 2008-04-30
JP2004525080A (ja) 2004-08-19
ZA200302772B (en) 2004-10-18
US20040157895A1 (en) 2004-08-12
NO20031510L (no) 2003-06-02
CN100421659C (zh) 2008-10-01
KR20030070003A (ko) 2003-08-27
EP1324753A2 (en) 2003-07-09
US6693129B2 (en) 2004-02-17
AU1145202A (en) 2002-04-15
PL365986A1 (en) 2005-01-24
UA77660C2 (en) 2007-01-15
PL212479B1 (pl) 2012-10-31
US7244749B2 (en) 2007-07-17
HUP0303040A3 (en) 2005-05-30
NO20031510D0 (no) 2003-04-03
RO120567B1 (ro) 2006-04-28
BR0114526A (pt) 2005-04-26
MXPA03002964A (es) 2004-12-06
US20020094996A1 (en) 2002-07-18
CN1477959A (zh) 2004-02-25
CA2424880A1 (en) 2002-04-11
WO2002028379A3 (en) 2003-02-27
RU2289406C2 (ru) 2006-12-20
NZ525390A (en) 2006-04-28
IL155238A0 (en) 2003-11-23
IL185384A (en) 2008-06-05
AU2002211452B2 (en) 2005-10-27
TR200300594T2 (tr) 2004-10-21
SK5252003A3 (en) 2004-01-08
CZ20031167A3 (cs) 2003-12-17
WO2002028379A2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
EE200300136A (et) Kompositsioonid ja meetodid lipoproteiin (a) taseme alandamiseks plasmas ja kardiovaskulaarsete haiguste riskifaktorite vähendamiseks
DE69938540D1 (de) Wechselstrom-plasmaanzeigetafel
AU2002306930A1 (en) Plasma processor and method for operating same
DE60214480D1 (de) Plasma Anzeigetafel
HK1070287A1 (en) Hepatitis c virus inhibitors
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
DE60227765D1 (de) Plasmabildschirm
DE60039581D1 (de) Plasma-Anzeigetafel
DE60136425D1 (de) Plasmaanzeigevorrichtung
AU2003212850A1 (en) Methods and compositions for treating cardiovascular disease
IL158927A (en) Method for virus propagation
DE60128192D1 (de) Plasma-Anzeigevorrichtung
DK1253248T3 (da) Rengöringsmaskine og fremgangsmåde til rengöring af ballast
GB2363676B (en) Plasma source
NO20012029L (no) Fremgangsmåte for ikke-repudiering ved bruk av kryptografiske signaturer i små enheter
FI20011947A (fi) Menetelmä suorittimen toiminnan ohjaamiseksi ja suoritin
GB0103526D0 (en) Composition and method for bleaching a substrate
GB0108737D0 (en) Composition and method for bleaching a substrate
DE50110998D1 (de) Plasmabildschirm
DE69911093D1 (de) Wechselstrom Plasma-Anzeigetafel
SE0000886D0 (sv) Composition affecting the level of high density lipoprotein cholesterol
DE29905658U1 (de) Hochfrequenz-Plasmabrenner
AU2002339012A1 (en) Method and machine for plasma sterilization
AU2002316420A1 (en) Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma
FI20012438A (fi) Menetelmä ja laitteisto kappaleiden puhdistamiseksi ja viimeistelemiseksi